Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2013 Jul;74(1):84-90.
doi: 10.1002/ana.23893. Epub 2013 Aug 6.

JC virus antibody status underestimates infection rates

Joseph R Berger  1 , Sidney A Houff, Julie Gurwell, Nubia Vega, Craig S Miller, Robert J Danaher
Affiliations

JC virus antibody status underestimates infection rates

Joseph R Berger et al. Ann Neurol. 2013 Jul.

Abstract

Objective: JC virus (JCV) seropositivity is a risk factor for progressive multifocal leukoencephalopathy (PML) in patients on natalizumab. Accordingly, the JCV serological antibody test is of paramount importance in determining disease risk.

Methods: We tested the accuracy of the JCV serum antibody test by comparing the results of JCV serology to JCV viruria and viremia in 67 patients enrolled in a single-center, retrospective cohort study. Bodily fluids (urine and blood) were assessed for JCV DNA by real time quantitative polymerase chain reaction 6 to 47 months (mean = 26.1 months) before JCV antibody testing. In 10 individuals, blood and urine samples were obtained on 2 separate occasions at 6-month intervals.

Results: Forty (59.7%) of the 67 patients were JCV seropositive. Of 27 JCV seronegative patients, 10 (37%) had JCV viruria. Urine JCV DNA copy numbers were significantly higher in the seropositive group (mean log copy number = 5.93, range = 1.85-9.21) than the seronegative group (mean log copy number = 2.41, range = 1.85-5.43; p = 0.0026). Considering all body fluid test results, 50 (74.6%) of the 67 patients were previously infected with JCV.

Interpretation: The false-negative rate of the JCV serology in this study was 37%; therefore, JCV serostatus does not appear to identify all patients infected with JCV. Thus, a negative JCV antibody result should not be conflated with absence of JCV infection. This discordance may be important in understanding JCV biology, risk for PML, and PML pathogenesis.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Comparison of JC virus antibody status in serum versus JC virus DNA status in urine. * - Not all patients provided urine at study visit.
Figure 2
Figure 2
Log10 values of urine virus in the JC virus antibody negative and positive groups
JCV antibody negative population (n=10)JCV antibody positive population (n=23)
 Mean log10 value = 2.657 Mean log10 value = 5.968
 Median log10 value = 2.2385(line) Median log10 value = 6.991 (line)
See this image and copyright information in PMC

References

    1. Kleinschmidt-DeMasters BK, Tyler KL. Progressive multifocal leukoencephalopathy complicating treatment with natalizumab and interferon beta-1a for multiple sclerosis. N Engl J Med. 2005;353:369–74. - PubMed
    1. Langer-Gould A, Atlas SW, Green AJ, Bollen AW, Pelletier D. Progressive multifocal leukoencephalopathy in a patient treated with natalizumab. N Engl J Med. 2005;353:375–81. - PubMed
    1. Van Assche G, Van Ranst M, Sciot R, et al. Progressive multifocal leukoencephalopathy after natalizumab therapy for Crohn’s disease. N Engl J Med. 2005;353:362–8. - PubMed
    1. Yousry TA, Major EO, Ryschkewitsch C, et al. Evaluation of patients treated with natalizumab for progressive multifocal leukoencephalopathy. N Engl J Med. 2006;354:924–33. - PMC - PubMed
    1. [Accessed August 20, 2012];TYSABRI Safety Update. 2012 at https://medinfo.biogenidec.com/medinfo/secure/pmlresource.do?resource=TY....

Publication types